Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
FAQ
- What is Mirum Pharmaceuticals, Inc.'s D&A?
- Mirum Pharmaceuticals, Inc. (MIRM) reported D&A of $6.94M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s D&A increased by 14.5% year-over-year, from $6.06M to $6.94M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s D&A has grown at a 152.7% compound annual growth rate (CAGR), from $595K to $24.24M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Mirum Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude